The following data were collected from each study: study design, presence of anti-Yo antibodies, sample size, the mean age of the sample, prognosis, patient history, treatments, imaging modalities, the time between the onset of cerebellar dysfunction and tumor identification, histological subtype, International Federation of Gynecology and Obstetrics (FIGO) staging, neurological assessment, explorative surgery performed, and laboratory results. The gene discussed is CDR2; the disease is neoplasm.